Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

doi:10.1159/000521683

Paper

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

Published Jan 28, 2022 · Christopher A. Legare, W. Raup-Konsavage, K. Vrana

Pharmacology

Q2 SJR score

124

Citations

4

Influential Citations

Full textSemantic Scholar

Abstract

Background: There is a growing interest in the use of cannabis (and its extracts), as well as CBD oil (hemp extracts containing cannabidiol), for therapeutic purposes. While there is reason to believe that cannabinoids may be efficacious for a number of different diseases and syndromes, there exist limited objective data supporting the use of crude materials (CBD oil, cannabis extracts, and/or cannabis itself). Summary: In the present review, we examined data for pure cannabinoid compounds (dronabinol, nabilone, and CBD), as well as partially purified medicinal cannabis extracts (nabiximols), to provide guidance on the potential therapeutic uses of high-THC cannabis and CBD oil. In general, data support a role for cannabis/cannabinoids in pain, seizure disorders, appetite stimulation, muscle spasticity, and treatment of nausea/vomiting. Given the biological activities of the cannabinoids, there may be utility in treatment of central nervous system disorders (such as neurodegenerative diseases, PTSD, and addiction) or for the treatment of cancer. However, those data are much less compelling. Key Message: On balance, there are reasons to support the potential use of medical cannabis and cannabis extract (Δ9-THC-dominant or CBD-dominant), but much more careful research is required.

Literature Review

Highly Cited

Study Snapshot

Key takeawayCannabis and CBD oil show potential in treating pain, seizure disorders, appetite stimulation, muscle spasticity, and nausea/vomiting, but more careful research is needed for central nervous system disorders and cancer treatment.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals

Sign up to use Study Snapshot

References

Citations

The Pharmacology of Cannabinoids in Chronic Pain

Cannabis and cannabinoids, particularly THC and CBD, show potential in reducing chronic pain disorders, with a combination of cannabinoids maximizing analgesic effects while minimizing side effects.

A Systematic Study of Liquid Chromatography in Search of the Best Separation of Cannabinoids for Potency Testing of Hemp-Based Products

The fastest separation of eighteen cannabinoids for potency testing of hemp-based products was achieved within 15.0 min using Raptor ARC-18 columns and a Cortecs Shield RP-18 column, with a slightly improved resolution.

Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges

Medical cannabis shows potential in reducing chronic pain intensity, but standardized dosing, long-term safety data, and regulatory frameworks are needed to fully integrate it into clinical practice.

Effects of a Cannabinoid-Based Phytocomplex (Pain ReliefTM) on Chronic Pain in Osteoarthritic Dogs

Pain ReliefTM, a cannabinoid-based nutritional supplement, reduces chronic pain in dogs with osteoarthritis by improving cytokine expression and oxidative status.

A Disposable Pipette Extraction-UHPLC-MS/MS Method Based on Removal of Phospholipids to Determine Anandamide, 2-Arachidonoylglycerol, Cannabidiol, and Δ9-Tetrahydrocannabidiol in Plasma Samples.

The DPX(Zr)-UHPLC-MS/MS method effectively determines CBD, THC, AEA, and 2-AG in plasma samples, with a fast and simple technique.

Cannabinoids as cytotoxic agents and potential modulators of the human parasite Trichomonas vaginalis.

Cannabinoids, specifically WIN 55,212-2, and Cannabivarin, show potential anti-parasitic effects and influence the growth and morphology of Trichomonas vaginalis, potentially offering a new treatment for trichomoniasis.